Prediction of Radionuclide Bone Imaging Findings by Gleason Histologic Grading of Prostate Carcinoma

Wj, Shih; Mitchell, Bonnie; Wierzbinski, Becky; Magocum, S; Uy, Ryo

doi:10.1097/00003072-199110000-00011

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present structured review, three cohort studies revealed superscans in 15%−23% of patients with prostate cancer and 1.3%−2.6% among patients with other types of cancer undergoing BS (Choi et al, 1995; Liu et al, 1996; Manohar et al, 2017; Shih et al, 1991; Simsek et al, 2020). In a large study with 6027 patients undergoing BS due to cancer, prostate cancer was the most common cause of superscans, followed by ductal breast carcinoma and lung and gastric cancer (Manohar et al, 2017).…”

Section: Discussionmentioning

confidence: 75%

“…A total of 13 cohort studies examining and reporting the presence of superscan in patients with cancer were included in the review. One study by Manohar et al (2017) examined the presence of superscan in a general population with cancer undergoing BS and four studies evaluated the frequency of superscan among patients diagnosed with a specific cancer type (Choi et al, 1995; Liu et al, 1996; Shih et al, 1991; Simsek et al, 2020) The study by Manohar et al included both retrospective and prospective data from a population of 6027 patients undergoing BS. overall, 80 cases of superscans were encountered corresponding to an frequency of 1.3% of all BS performed (Manohar et al, 2017).…”

Section: Resultsmentioning

confidence: 99%

“…One study evaluated the relationship between Gleason score (GS) and Tc-99 m HMDP bone scans in patients with prostate cancer, showing that superscans and extensive metastases only occurred in patients with high GS >6, thus superscan was seen in 11 of the 32 men with high GS, whereas, no superscan pattern was seen among the 16 men with low GS (Shih et al, 1991). Another study in prostate cancer patients revealed that 23/138 (16.7%) patients had a superscan pattern on BS (Simsek et al, 2020).…”

Section: Cohort Studies With Malignancymentioning

confidence: 99%

See 2 more Smart Citations

Frequency of superscan on bone scintigraphy: A systematic review

Kovacsne

Kozon

Bentestuen

2023

Clin Physio Funct Imaging

View full text Add to dashboard Cite

Introduction Bone scintigraphy (BS) is an important tool for detecting bone metastasis. BS with diffuse increased skeletal radioisotope uptake with absent or faint urinary tract and soft tissue activity is defined as a superscan. In this review, we investigate the different etiologies causing superscan and the reported frequency of superscan among different disease entities. Materials and Methods The search terms were ‘bone’ AND ‘superscan’ OR ‘superscan’ in the PubMed database from 1980 to November 2020. Eligibility criteria included the following: Peer‐reviewed studies containing original data using 99mTc‐phosphate‐analogue BS reporting a superscan pattern. Unretrievable papers, imaging modalities other than BS or with insufficient information to assess the aetiology were excluded. The abstracts of every paper and full texts of potentially eligible papers were assessed independently by three observers. Results Sixty‐seven papers were included (48 case reports and 19 cohort studies). Studies conducted in patients with osteomalacia or skeletal fluorosis revealed superscan in all patients. Other benign causes of superscan were hyperparathyroidism and kidney disease. Among papers with malignant cause, prostate cancer was the most common cause, followed by gastric cancer. The frequency of superscans ranged from 1.3% in a cohort of mixed cancer types up to 2.6% in patients with gastric cancer and up to 23% in a cohort of prostate cancer patients. Conclusion Superscan is most frequently seen in prostate cancer, but numerous other cancers and metabolic bone diseases can cause superscan, which should be kept in mind when encountering an unexpected superscan on BS.

show abstract

Section: Discussionmentioning

confidence: 75%

Section: Resultsmentioning

confidence: 99%

Section: Cohort Studies With Malignancymentioning

confidence: 99%

See 1 more Smart Citation

Frequency of superscan on bone scintigraphy: A systematic review

Kovacsne

Kozon

Bentestuen

2023

Clin Physio Funct Imaging

View full text Add to dashboard Cite

show abstract

“…Biological activity of prostate cancer relates to its histological appearance. Histological appearance is graded as: well, moderately well, and poorly differentiated 2 Gleason's grading system is widely used [3,4] and correlates well with mortality or morbidity including prediction of skeletal metastasis [5] . Prostate specific antigen (PSA) and prostate acid phosphatase (PAP), tumor markers of prostate carcinoma, have been used to confirm diagnosis and to monitor therapy of prostate carcinoma [6][7][8][9] .…”

Section: Introductionmentioning

confidence: 99%

Correlation of serum PSA levels with Gleason score in patients with prostatic Adenocarcinoma

Mustaq¹,

Reshi²,

Mehmood³

et al. 2020

Int. J. Clin. Diagn. Pathol.

View full text Add to dashboard Cite

In order to see a relationship between gleason scores on histopathology and PSA levels, group of 200 men were studied which included obtaining there cumulative Gleason score and serum PSA levels before surgical intervention. Two groups were obtained, 178 cases with high (6-10) and 22 with low (2-5) Gleason score. Mean S.PSA levels in patients with high gleason score was 128ng/ml (normal range 0 to 5) and mean PSA levels for patients with low scores was 25ng/ml. The group with high gleason score showed greater increase in serum PSA levels than lower gleason score.

show abstract

Bone scintigraphy predicts the risk of spinal cord compression in hormone-refractory prostate cancer

Soerdjbalie‐Maikoe

Pelger

Nijeholt

et al. 2004

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

In prostate cancer, confirmation of metastatic involvement of the skeleton has traditionally been achieved by bone scintigraphy, although the widespread availability of prostate-specific antigen (PSA) measurements has tended to eliminate the need for this investigation. The potential of bone scintigraphy to predict skeletal-related events, particularly spinal cord compression, after the onset of hormone refractoriness has never been investigated. The aim of this study was to establish whether a new method of evaluating bone scintigraphy would offer a better predictive value for this complication of the metastatic process than is achieved with currently available grading methods. We studied 84 patients with hormone-refractory prostate cancer who had undergone bone scintigraphy at the time of hormone escape. Tumour grading and parameters of tumour load (PSA and alkaline phosphatase activity) were available in all patients. The incidence of spinal cord compression was documented and all patients were followed up until death. Bone scintigraphy was evaluated by the conventional Soloway grading and by an additional analysis determining total or partial involvement of individual vertebrae. In contrast to the Soloway method, the new method was able to predict spinal cord compression at various spinal levels. Our data suggest that there is still a place for bone scintigraphy in the management of hormone-refractory prostate cancer.

show abstract

Prediction of Radionuclide Bone Imaging Findings by Gleason Histologic Grading of Prostate Carcinoma

Cited by 5 publications

References 0 publications

Frequency of superscan on bone scintigraphy: A systematic review

Frequency of superscan on bone scintigraphy: A systematic review

Correlation of serum PSA levels with Gleason score in patients with prostatic Adenocarcinoma

Bone scintigraphy predicts the risk of spinal cord compression in hormone-refractory prostate cancer

Contact Info

Product

Resources

About